Karyopharm Accounting Chief Sells Small Stake to Cover Taxes as PSUs Vest
Kristin Abate, Chief Accounting Officer at Karyopharm Therapeutics Inc., executed a pre-arranged sale of 50 shares on January 28 at $7.03 to meet withholding tax obligations tied to vested performance-based restricted stock units. The transactions leave Abate with 22,622 shares and occur as the company approaches upcoming earnings and a Phase III r…